Search
Now showing items 1-10 of 13
Comparison Of Myeloablative Versus Reduced-Intensity Conditioning Regimens For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia: A Cohort Study
(2019)
Objective: Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for a variety of malignant and non-malignant hematologic disorders. Myeloablative conditioning (MAC) and reduced-intensity ...
Unclassifiable Non-Cml Classical Myeloproliferative Diseases With Microcytosis: Findings Indicating Diagnosis Of Polycythemia Vera Masked By Iron Deficiency
(2019)
Background/aim Polycythemia Vera (PV) is a myeloproliferative disorder characterized by overproduction of morphologically normal red blood cells (RBCs), granulocytes, and platelets, a phenotype that is caused by a mutation ...
Mitoxantrone-Melphalan Conditioning Regimen For Autologous Stem Cell Transplantation In Relapsed/Refractory Lymphoma
(2019)
Background/aim High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL). ...
Expression Profiles Of The Individual Genes Corresponding To The Genes Generated By Cytotoxicity Experiments With Bortezomib In Multiple Myeloma
(2016)
Objective: Multiple myeloma (MM) is currently incurable due to refractory disease relapse even under novel anti-myeloma treatment. In silico studies are effective for key decision making during clinicopathological battles ...
Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells
(2014)
Objective: The prominent functions of the local renin-angiotensin system (RAS) in primitive hematopoiesis further support the hypothesis that local autocrine bone marrow RAS could also be active in neoplastic hematopoiesis. ...
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
(2015)
Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful ...
Co-Expression Of T(15;17) And T(8;21) In A Case Of Acute Promyelocytic Leukemia: Review Of The Literature
(2013)
Additional chromosomal abnormalities in acute myelogenous leukemia have been identified as one of the most important prognostic factors. Favorable chromosomal changes such as t(8;21), inv(16), and t(15;17) are associated ...
The Prognosis Of Adult Burkitt’S Cell Leukemia In Real-Life Clinical Practice
(2016)
Objective: Many studies reported an improved prognosis in patients with Burkitt’s lymphoma obviating the need of stem cell transplantation. However, prognosis of the advanced disease [i.e. Burkitt’s cell leukemia (BCL)] ...